Select date
In the Midst of Crisis, FDA Approves Opioid Drug 10X Stronger than Fentanyl Funded by DoD
The FDA has approved the rollout of a new opioid drug up to 1000 times stronger than morphine, despite the opioid crisis that is currently killing more Americans than any other cause of accidental death.
The agency sided with its Anesthetic and Analgesic Advisory Panel, which voted 10-3 to approve Dsuvia, a sublingual tablet form of sufentanil, against the recommendation of its chairman. At 5-10 times the strength of fentanyl, sufentanil is 500-1000 times stronger than morphine, and will supposedly only be administered to treat acute pain in medically-supervised settings.
Fentanyl, too, is available only by prescription, yet a significant quantity is manufactured in illegal labs or diverted to the street, where it regularly kills opioid addicts who aren’t even aware they are taking it.
Dsuvia is fulfilling an “unmet need,” says Dr Pamela Palmer, chief medical officer of AcelRx, which makes the drug. Because the drug dissolves under patients’ tongues, it provides quick relief without the use of an injection. Still, because it must be delivered in a medical setting and doctors and nurses are trained to give injections, there are relatively few situations in which it offers an advantage that outweighs the risk of unleashing a powerful new narcotic onto an already drug-saturated populace.
The Department of Defense had a hand in funding the research that produced Dsuvia, which could replace morphine on the battlefield due to its ease of administration. AcelRx projects $1.1 billion in annual sales and hopes to have its product on hospital shelves by early 2019.
Palmer claims the drug will be subjected to much stricter audits and monitoring than earlier opioids like Oxycontin, which became so ubiquitous in rural America after it was introduced by Purdue Pharmaceuticals that it earned the nickname “hillbilly heroin.” Drug manufacturers flooded small towns with millions of pills, filling huge pharmacy orders out of proportion to the population of the surrounding areas.
With 200 million prescriptions already written for opioids every year in the US, many argue Americans don’t need another drug. Dr. Sidney Wolfe, senior adviser to Public Citizen’s Health Research Group, dismisses Palmer’s claims about the fast action of Dsuvia: two studies indicated patients only felt “meaningful” pain relief after 54 minutes and 78 minutes, making the new drug no better than swallowing a pill.
Over 72,000 Americans died of drug overdoses last year – a new record – and among the drugs causing overdose, the largest increase was in fentanyl and fentanyl-like synthetics.
The US Food and Drug Administration approved a cannabis-based drug for the first time, the agency said Monday. Epidiolex was recommended for approval by an advisory committee in April, and the agency had until this week to make a decision. The twice-daily oral solution is approved for use in patients 2 and older to treat two types of epileptic syndromes: Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life, and Lennox-Gastaut syndrome, a form of epilepsy with multiple types of seizures that begin in early childhood, usually between 3 and 5.
A new pill that tells your doctor whether you're swallowing it or not has just been approved by the Food and Drug Administration.
The historic Nov. 2016 ballot initiatives to legalize cannabis brought a resounding win for freedom in several states, with the exception of Arizona. There, voters narrowly rejected decriminalization, in no small part due to a massive anti-pot propaganda campaign funded in-part by Big Pharma.
While more and more people are becoming educated about the true history of Monsanto and genetically engineered foods, most still don’t realize one extremely important piece of information: the FDA’s surprising lack of safety testing. In regards to GMOs, the FDA’s declaration of “substantial equivalence” means that there is no long-term, independent safety testing of new foods and crops that have been genetically engineered.
The Food and Drug Administration (FDA) on Monday approved the use of an experimental drug that has been hailed as one of the pharmaceutical industry's best chances at fighting the Ebola virus.
The PillCam is being slated for those patients who are not candidates for colonoscopies which translates to nearly 750,000 in the US alone.
Amid the most severe influenza season in more than a decade, federal health officials on Wednesday approved a next-generation, insect-based flu vaccine that sidesteps the thorniest parts of production -- and will be used immediately in people willing to test it.
